Published • loading... • Updated
Biogen Pens $1bn Deal to Buy Immunology Biotech RayThera
The deal expands Biogen’s immunology pipeline with multiple anti-inflammatory assets and a lead candidate expected to enter Phase 1 development this year.
- On Wednesday, Biogen agreed to acquire San Diego-based RayThera for up to $1 billion, consisting of an upfront payment and clinical and regulatory milestone payments.
- Founded in 2023 by biotech veterans Qing Dong and Gene Hung, RayThera focuses on developing safer, more effective therapies for immunological diseases.
- Patent applications linked to the startup reveal work on TNF activity modulators, CCR4 inhibitors, and STAT6 modulators targeting various immune-mediated conditions.
- This transaction follows Biogen's recent $5.6 billion acquisition of Apellis Pharmaceuticals, as the company seeks to shore up its portfolio amid biosimilar competition to Tysabri.
- Biogen will lead development, manufacturing and globalization of the acquired assets, with the lead candidate expected to enter Phase 1 development in early Q3 2026.
Insights by Ground AI
12 Articles
12 Articles
Biogen to acquire RayThera in deal valued up to $1B
Biogen (BIIB) has entered into a definitive agreement to acquire private biotechnology firm RayThera Inc. in a transaction valued at up to $1B. The strategic acquisition focuses on expanding Biogen’s long-term pipeline footprint within the high-growth
·United States
Read Full Article
The Hamilton Spectator+3 Reposted by 3 other sources
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, today announced the companies have entered into a…
·Hamilton, Canada
Read Full Article
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources12
Leaning Left2Leaning Right2Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 22%
C 56%
R 22%
Factuality
To view factuality data please Upgrade to Premium
